A Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/III Colorectal Cancer
- Conditions
- Colorectal CancerBowel Cancer
- Interventions
- Drug: Placebo
- Registration Number
- NCT02633098
- Lead Sponsor
- St George's, University of London
- Brief Summary
This study evaluates the safety and effectiveness of pre-operative artesunate given orally once a day for 14 days prior to surgery in patients with Stage II/III colorectal cancer.
Artesunate is an established antimalarial drug with an excellent safety profile, is well tolerated and affordable. A number of laboratory studies and one small pilot clinical study in patients with colorectal cancer have shown that artesunate can reduce the proliferation and growth of cancer cells.
Two hundred patients diagnosed with Stage II/III operable colorectal cancer will be randomly allocated to receive oral artesunate 200mg daily or a matching placebo for 14 days prior to surgery. Patients will be followed up closely for 5 years to see if giving artesunate preoperatively reduces the risk of cancer recurring after surgery.
- Detailed Description
Artesunate is an established antimalarial drug belonging to the artemisinin class of drugs, has an excellent safety profile, is well tolerated and affordable. In last two decades, artemisinins have shown potent and broad anticancer properties in a range of cell lines and animal models, supporting the hypothesis that artemisinins have the potential to be an effective anti-cancer therapy. Multiple potential mechanisms of action include anti-proliferative effects through cell-cycle disruption, reactive oxygen species (ROS) -induced DNA damage, induction of apoptosis, anti-angiogenesis, immunomodulation and induced radiosensitivity.
Despite a multi-modality treatment approach to colorectal cancer, 5 year overall survival does not currently exceed 60%. Neoadjuvant pre-operative therapy may be more effective at eradicating micrometastases compared to adjuvant therapy delivered following the delay and immunological stress of surgery. However current neoadjuvant chemotherapy regimens are often associated with significant side effects and may result in a delay in surgery whilst patients recover. A well tolerated, affordable, novel anticancer agent that could be given to patients whilst they wait for surgery, without causing a surgical delay due to treatment related toxicity, would have a significant clinical impact on patient care.
The NeoART trial is a phase II multicentre randomised, double blind, placebo controlled trial (RCT) for patients undergoing primary surgery for Stage II/III colorectal cancers. Patients are randomised (1:1 ratio) to receive either a two week course of neoadjuvant artesunate 200mg once daily or matching placebo. Both patients and health care professionals are blinded to treatment allocation arm to minimise outcome-reporting bias. The primary endpoint of the trial is recurrence free survival two years after surgery. Secondary endpoints include 2 and 5 year overall survival, treatment related toxicity, tolerability and patient quality of life. A translational sub-study looking at predictive and prognostic biomarkers is also planned.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 200
Not provided
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Artesunate Artesunate 200mg Artesunate 200mg oral tablets once daily for 14 days. Matching placebo Placebo Matching placebo oral tablets once daily for 14 days.
- Primary Outcome Measures
Name Time Method Recurrence free survival at 2 years 2 years following study randomisation.
- Secondary Outcome Measures
Name Time Method Immunohistochemical analyses of paraffin-embedded tumour for v-Raf murine sarcoma viral oncogene homolog B (BRAF) mutation status Pre and post intervention tumour samples from patients (Day 0 and Day 15) Number of patients with BRAF mutant tumours
Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor (PDGF) expression Pre and post intervention tumour samples from patients (Day 0 and Day 15) Number of patients whose tumours show PDGF upregulation/downregulation following treatment intervention
Recurrence free survival at 5 years 5 years from study randomisation Overall survival at 2 and 5 years 2 and 5 years from study randomisation Colon cancer specific death at 2 and 5 years 2 and 5 years from study randomisation Adverse events affecting patients as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment 60 months following study intervention Pathological assessment of tumour regression (involvement of lymph nodes; serosa; resection margin) Post surgical pathology review (following Day 14 of study intervention) Patient quality of life Assessment at Day 42 of study intervention Using validated quality of life self-administered questionnaires
Immunohistochemical analyses of paraffin-embedded tumour sections to assess Mismatch Repair (MMR) status Pre and post intervention tumour samples from patients (Day 0 and Day 15) Number of patients with Mismatch Repair (MMR) mutant tumours
Number of patients experiencing artesunate drug related toxicity as assessed by Common Terminology Criteria for Adverse Events (CTCAE) v4.0 Assessment at Day 42 following start of study intervention (artesunate/matching placebo) Surgical complications From time of surgery up to 3 months post surgery Number of patients with surgery related adverse events as assessed by CTCAE v4.0
Predictive value of tumour marker Carcinoma Embryonic Antigen (CEA) kinetics in terms of predicting response to artesunate therapy Assessment at Day 42 of study intervention Immunohistochemical analyses of paraffin-embedded tumour sections to assess Kirsten rat sarcoma viral oncogene homolog (Kras) mutation status Pre and post intervention tumour samples from patients (Day 0 and Day 15) Number of patients with Kras mutant tumours
Immunohistochemical analyses of paraffin-embedded tumour for Vascular endothelial Growth Factor (VEGF) expression Pre and post intervention tumour samples from patients (Day 0 and Day 15) Number of patients whose tumours show VEGF upregulation/downregulation following study intervention
Immunohistochemical analyses of paraffin-embedded tumour for Platelet derived growth factor receptor (PDGFR) expression Pre and post intervention tumour samples from patients (Day 0 and Day 15) Number of patients whose tumours show PDGFR upregulation/downregulation following study intervention
Immunohistochemical analyses of paraffin-embedded tumour on Vascular endothelial Growth Factor Receptor (VEGFR) expression Pre and post intervention tumour samples from patients (Day 0 and Day 15) Number of patients whose tumours show VEGFR upregulation/downregulation following study intervention
Determination of proliferative activity (Ki-67 staining, Cluster of Differentiation 31 protein (CD31) staining) Pre and post intervention tumour samples from patients (Day 0 and Day 15) Number of patients whose tumours show an increase or reduction in proliferation markers Ki67 and CD31 following study intervention
Determination of activation of the Deoxyribonucleic acid damage response (DDR) pathway Pre and post intervention tumour samples from patients (Day 0 and Day 15) Number of patients whose tumour samples show activation of the DDR pathway following study intervention
Wnt/β-catenin proliferation pathway protein expression (e.g. c-myc and cyclinD1 proteins) Pre and post intervention tumour samples from patients (Day 0 and Day 15) Number of patients who show an increase or a decrease in expression of proteins involved in the Wnt/β-catenin proliferation pathway (e.g. c-myc and cyclinD1 proteins) following study intervention
Trial Locations
- Locations (8)
Barking, Havering and Redbridge University Hospitals NHS Trust
🇬🇧Barking, United Kingdom
Medway Maritime Hospital
🇬🇧Gillingham, Kent, United Kingdom
Kent Oncology Centre, Maidstone Hospital
🇬🇧Maidstone, Kent, United Kingdom
St George's University Hospitals NHS Fundation Trust
🇬🇧London, United Kingdom
Ashford & St Peters Hospital NHS Foundation Trust
🇬🇧Chertsey, United Kingdom
Norfolk & Norwich University Hospitlas NHS FT
🇬🇧Norwich, United Kingdom
Shrewsbury and Telford Hospital NHS Trust
🇬🇧Shrewsbury, United Kingdom
University Hospitals of Derby and Burton NHS Foundation Trust
🇬🇧Derby, United Kingdom